Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

Recruiting

• Conditions: Endocan; Copeptin; Serum; Preterm Neonates; Respiratory Distress Syndrome

• Registration Number: NCT07154134
• Lead Sponsor: Tanta University

Brief Summary

This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.

Detailed Description

Preterm birth continues to be one of the significant challenges in perinatal medicine because of its high incidence of morbidities and mortalities. Its burden on the infant, the family, healthcare systems, and society is enormous.

Endocan is implicated in the recruitment of circulating lymphocytes to inflammatory sites and leukocyte adhesion and activation. Endocan also inhibits leukocyte-endothelial cell adhesion and reduces the excessive leukocyte recruitment into the lungs.

Copeptin, also known as the arginine vasopressin (AVP) associated glycopeptides. AVP is a vasoactive neurohypophysial hormone. It is one of the primary hormones of the hypothalamic-pituitary-adrenal axis, and its primary function is to regulate water and maintain electrolyte homeostasis. The primary stimulus for AVP release is hyperosmolarity.

Study Timeline

• Study Start: 2025-07-10
• Status Verified: 2025-08
• Study First Submitted: 2025-08-27
• Study First Submitted QC: 2025-08-27
• Last Update Submitted: 2025-08-27
• Study First Posted: 2025-09-04
• Last Update Posted: 2025-09-04
• Primary Completion: 2025-11-01
• Study Completion: 2025-11-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Prematurity.
• Gestational age between 28 and 36 weeks.
• Suffering from respiratory distress syndrome.

Exclusion Criteria

• Intrauterine growth restriction (IUGR).
• Hypoxic ischemic encephalopathy.
• Multiple congenital anomalies.
• Chromosomal abnormalities.
• Preterm less than 28 weeks.
• Neonates with a maternal history of chorioamnionitis (early sepsis).
• Infant of diabetic mother.
• Prelabor rupture of membranes (PROM)> 2 hours.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum endocan level for prediction of severity of respiratory distress syndrome	First day of life	Serum endocan level for prediction of severity of respiratory distress syndrome (RDS) will be recorded.

Secondary Outcome Measures

Name	Time	Method
Serum copeptin level for prediction of severity of respiratory distress syndrome	5th day of life	Serum copeptin level for the prediction of the severity of respiratory distress syndrome (RDS) will be recorded.
Serum endocan level for prediction of mortality	First day of life	Serum endocan level for prediction of mortality will be recorded.
Serum copeptin level for prediction of mortality	5th day of life	Serum copeptin level for prediction of mortality will be recorded.

Trial Locations

Locations (1)

Tanta University; 🇪🇬 Tanta, El-Gharbia, Egypt